Prodrug Information
| Prodrug General Information | Top | |||||
|---|---|---|---|---|---|---|
| Prodrug ID |
D37JPB
|
|||||
| Prodrug Name |
PMID26729077-Compound-36
|
|||||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |||
| Activation |
Prodrug 
|
|
Parent Drug 
|
|||
| 2D MOL | 2D MOL | |||||
| Prodrug Strategy |
Classical prodrug strategy
[Carrier linked prodrug]
|
|||||
| Improved property |
Increase solubility
|
[1] | ||||
| Description |
PMID26729077-Compound-36 is more active and approximately 36-fold more soluble than DW2282 (0.865, 0.024 mg/ml respectively).
|
[1] | ||||
| Parent Drug General Information | Top | |||||
|---|---|---|---|---|---|---|
| Parent Drug ID |
D56RYX
|
|||||
| Parent Drug Name |
DW2282
|
|||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Investigation of amino acid conjugates of (S)-1-[1-(4-aminobenzoyl)-2,3-dihydro-1H-indol-6-sulfonyl]-4-phenyl-imidazolidin-2-one (DW2282) as water soluble anticancer prodrugs. Eur J Med Chem. 2014 Jun 10;80:439-46. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.